Fundación para la Investigación Biomédica del Hospital 12 de Octubre Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2013
NCT02481934
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Carmen Rosa Pallas | Fundación para la Investigación Biomédica del Hospital 12 de Octubre | Hospital Universitario 12 de Octubre de Madrid | HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, MADRID | Ignacio Saez de la Fuente | Jesús González de la Aleja Tejera | Joaquín Martínez López, MD, PhD

Active Ingredients

Drugs in Phase 4 Trials (3)

capecitabine (xeloda) (1 trial)

dapagliflozin (farxiga) (1 trial)

gemcitabine (gemzar) (1 trial)

Drugs in Phase 3 Trials (1)

valganciclovir (Valcyte) (1 trial)

Drugs in Phase 1 Trials (3)

bortezomib (velcade) (1 trial)

lenalidomide (revlimid) (1 trial)

nkae cells (1 trial)

Drugs in Other Trials (2)

human milk (1 trial)

l-glutamine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholangiocarcinoma (Phase 4)

Cytomegalovirus Infections (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Klatskin Tumor (Phase 4)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Pneumonia (Phase 3)

Tuberculosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 9